Feedback on widening access to denosumab

About this form

Please note:

You cannot save your progress.
The form does not register text formatting, such as bold or hyperlinks.
There is no character limit on any field.
You should receive an email with a summary of your feedback when you submit the form.

Do you have any comments or feedback you would like to provide about the proposal?

Do you have any comments or feedback you would like to provide about the special authority criteria and its use in clinical practice?

Do you think the proposed criteria would capture the people intended for funded access to denosumab? If no, please explain the changes we should consider.

Do you have any lived experience that you would like to share that is relevant to Pharmac's consideration of this proposal?

Your name (optional)

Your email

This field is required, if you do not wish to share your email, you can leave the default text in the field.

Your role (optional)

(for example, GP, endocrinologist, oncologist, person with osteoporosis or cancer)

Your organisation (optional)

Your feedback may be shared

When you give feedback on a consultation, your feedback becomes official information that Pharmac holds. Pharmac has legal responsibilities for how we manage this official information, under laws such as the Official Information Act and Privacy Act.

Pharmac may receive a request from people for official information, which could include your feedback. Legally, Pharmac must consider whether your feedback should be released.

We will consider your views when assessing whether the feedback has to be released.

If your feedback is proposed for release, then Pharmac will contact you, unless there is a legal reason that we can't.

Note that Pharmac collects and holds your information in line with our Privacy Statement

Tell us if there is anything about your feedback that you would prefer wasn’t released.